Literature DB >> 1970503

The beta 1- and beta 2-adrenoceptor affinity and beta 1-blocking potency of S- and R-metoprolol.

G Wahlund1, V Nerme, T Abrahamsson, P O Sjöquist.   

Abstract

1. The beta-adrenoceptor affinity and blocking potency of the two enantiomers and the racemate of metoprolol were investigated in vitro, by use of a receptor-binding technique, and in vivo in the anaesthetized cat. 2. The enantiomeric purity of the S- and R-form was: greater than 99.2% and greater than 99.9%, respectively. 3. The beta 1- and beta 2-adrenoceptor affinity (-log equilibrium dissociation constant) of the enantiomers was determined from competition binding experiments (radioligand: [125I]-(S)-pindolol) performed in membranes prepared from the guinea-pig left ventricular free wall (predominantly beta 1) and soleus muscle (beta 2). The beta 1-adrenoceptor affinity was (means +/- s.d.): 7.73 +/- 0.10 and 5.00 +/- 0.06 for the S- and R-form of metoprolol, respectively. The corresponding values for beta 2-adrenoceptors were 6.28 +/- 0.06 (S) and 4.52 +/- 0.09 (R). Thus, the difference in affinity for the two enantiomers was greater on beta 1- (about 500) than on beta 2-adrenoceptors (about 50). The beta 1-adrenoceptor selectivity of the S-form (about 30) was similar to that of the racemic metoprolol, while the R-form was almost non-selective (3 fold beta 1-selective). 4. In the anaesthetized cat, the (-log) intravenous doses (mumol kg-1) of S- and R-metoprolol causing a 50% reduction (ED50) in the heart rate response to sympathetic nerve stimulation were determined. The doses inducing a 25% depression (DD25) of the basal myocardial contractility were also estimated. For the two enantiomers, the beta 1-blocking potency (-log ED50) was 7.04 +/- 0.16 (S) and 4.65 +/- 0.16 (R). A significant cardiodepressive effect was observed at high doses (-log DD25): 4.18 + 0.20 (S) and 4.08 + 0.10 (R). 5. It is concluded that the binding of metoprolol to beta 1-adrenoceptors has a stricter steric requirement than that for the binding of this beta l-blocker to beta 2-adrenoceptors. Furthermore, the non-specific cardiodepressive effect of metoprolol was observed at equally high doses for the two enantiomers.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1970503      PMCID: PMC1917361          DOI: 10.1111/j.1476-5381.1990.tb12974.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

1.  Influence of lipophilicity and chirality on the selectivity of ligands for beta 1- and beta 2-adrenoceptors.

Authors:  N el Tayar; B Testa; H van de Waterbeemd; P A Carrupt; A J Kaumann
Journal:  J Pharm Pharmacol       Date:  1988-09       Impact factor: 3.765

2.  Absolute configuration by asymmetric synthesis of (+)-1-(4-acetamidophenoxy)-3-(isopropylamino)-propan-z-ol (practolol).

Authors:  J C Danilewicz; J E Kemp
Journal:  J Med Chem       Date:  1973-02       Impact factor: 7.446

3.  A model for the interaction of competitive antagonists with two receptor-subtypes characterized by a Schild-plot with apparent slope unity. Agonist-dependent enantiomeric affinity ratios for bupranolol in tracheae but not in right atria of guinea pigs.

Authors:  H Lemoine; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-03       Impact factor: 3.000

4.  Selectivity and steric effects of metoprolol isomers on isolated rabbit atria, arteries and tracheal muscles.

Authors:  N Toda; S Hayashi; Y Hatano; H Okunishi; M Miyazaki
Journal:  J Pharmacol Exp Ther       Date:  1978-11       Impact factor: 4.030

5.  The effects of three beta-adrenoceptor blocking drugs on isolated preparations of skeletal and cardiac muscle.

Authors:  J D Harry; R J Linden; H M Snow
Journal:  Br J Pharmacol       Date:  1974-10       Impact factor: 8.739

Review 6.  Molecular geometry and adrenergic drug activity.

Authors:  P N Patil; D D Miller; U Trendelenburg
Journal:  Pharmacol Rev       Date:  1974-12       Impact factor: 25.468

7.  Cardiac effects of beta-adrenergic receptor antagonists.

Authors:  B Ablad; B Carlsson; E Carlsson; C Dahlöf; L Ek; E Hultberg
Journal:  Adv Cardiol       Date:  1974

8.  Effects on exercise tachycardia during forty-eight hours of a series of doses of atenolol, sotalol, and metoprolol.

Authors:  D W Harron; K Balnave; C D Kinney; R Wilson; C J Russell; R G Shanks
Journal:  Clin Pharmacol Ther       Date:  1981-03       Impact factor: 6.875

9.  Evidence that (+)-bupranolol interacts directly with myocardial beta-adrenoceptors. Control of optical purity with differential thermal analysis.

Authors:  W Wächter; U Münch; H Lemoine; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-08       Impact factor: 3.000

10.  A study designed to explore the hypothesis that beta-1 adrenoceptors are "innervated" receptors and beta-2 adrenoceptors are "hormonal" receptors.

Authors:  L J Bryan; J J Cole; S R O'Donnell; J C Wanstall
Journal:  J Pharmacol Exp Ther       Date:  1981-02       Impact factor: 4.030

View more
  6 in total

1.  Influence of gestational diabetes on the stereoselective pharmacokinetics and placental distribution of metoprolol and its metabolites in parturients.

Authors:  Natalícia de Jesus Antunes; Ricardo Carvalho Cavalli; Maria Paula Marques; Elaine Christine Dantas Moisés; Vera Lucia Lanchote
Journal:  Br J Clin Pharmacol       Date:  2015-04       Impact factor: 4.335

2.  Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine.

Authors:  Stephen M Stout; Jace Nielsen; Lynda S Welage; Michael Shea; Robert Brook; Kevin Kerber; Barry E Bleske
Journal:  J Clin Pharmacol       Date:  2010-04-16       Impact factor: 3.126

3.  The design, synthesis and pharmacological characterization of novel β₂-adrenoceptor antagonists.

Authors:  J Daniel Hothersall; James Black; Stephen Caddick; Jeremy G Vinter; Andrew Tinker; James R Baker
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

4.  Pharmacological characterization and anatomical localization of prejunctional beta-adrenoceptors in the rat kidney.

Authors:  P P Lakhlani; F Amenta; P Napoleone; L Felici; D C Eikenburg
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

5.  Receptor binding assays in analysing the bioavailability and pharmacodynamic bioequivalence of active drug moieties. A study of metoprolol.

Authors:  T Kaila; L Roivas; P J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

6.  Development of a sensitive and rapid method for quantitation of (S)-(-)- and (R)-(+)-metoprolol in human plasma by chiral LC-ESI-MS/MS.

Authors:  Primal Sharma; Pritesh Contractor; Swati Guttikar; Daxesh P Patel; Pranav S Shrivastav
Journal:  J Pharm Anal       Date:  2013-03-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.